Nasser Tehrani, MD
Interventional Cardiology · Perry, GANPI 1831185388
Payments from drug & device makers
Across 174 payments — averaging $55.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Medical Device Business Services, Inc.$817
- Cardiovascular Systems Inc.$776
- Philips North America LLC$708
- Merck$374
- Shockwave Medical, Inc$297
- plus $2K from 24 others
What the payments were for
- Travel & lodging$5,38956%
- Food & beverage$4,23144%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 25 | $4,509 |
| Medical Device Business Services, Inc. | 32 | $817 |
| Cardiovascular Systems Inc. | 3 | $776 |
| Philips North America LLC | 11 | $708 |
| Merck | 20 | $374 |
| Shockwave Medical, Inc | 2 | $297 |
| Boston Scientific | 4 | $273 |
| Esperion Therapeutics, Inc. | 10 | $226 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $189 |
| Abbott | 5 | $181 |
| Abiomed | 4 | $173 |
| Pfizer | 7 | $137 |
| Novo Nordisk | 1 | $127 |
| Sanofi-aventis U.S. LLC | 1 | $124 |
| AstraZeneca | 7 | $110 |
| Novartis | 6 | $108 |
| Chiesi USA, Inc. | 4 | $84 |
| Johnson & Johnson | 3 | $67 |
| Amgen | 4 | $63 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Heartflow, Inc. | 1 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Lilly USA, LLC | 1 | $27 |
| Vital Connect, Inc | 1 | $26 |
| Cvrx, Inc. | 1 | $23 |
| Penumbra, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Cardinal Health 200 LLC | 1 | $18 |
| Vertex | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Advisa$2,331
- RESOLUTE ONYX$1,385
- Peripheral Orbital Atherectomy System$766
- Carto 3$514
- ELCA$394
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$297
- (6571) Eagle Eye$135
- NEXLIZET$125
- NEXLETOL$125
- Adapta$103
- CARDIOMEMS$103
How this compares
$9,634 in reported general payments places this provider in the 50th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 596 | $597,474 |
| EntrestoSacubitril/Valsartan | 274 | $317,904 |
| Repatha SureclickEvolocumab | 225 | $187,697 |
| Repatha SyringeEvolocumab | 80 | $87,625 |
| FarxigaDapagliflozin Propanediol | 84 | $85,130 |
| BrilintaTicagrelor | 110 | $84,098 |
| OzempicSemaglutide | 58 | $80,175 |
| VerquvoVericiguat | 86 | $77,221 |
| XareltoRivaroxaban | 83 | $76,190 |
| Ranolazine ErRanolazine | 612 | $66,164 |
| NexlizetBempedoic Acid/Ezetimibe | 58 | $44,978 |
| Ezetimibe | 1,117 | $15,989 |
| Praluent PenAlirocumab | 17 | $13,628 |
| ClopidogrelClopidogrel Bisulfate | 1,083 | $11,038 |
| Atorvastatin Calcium | 1,050 | $9,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $137 | $597,474596 claims |
| NovartisEntresto | $108 | $317,904274 claims |
| AstraZenecaFarxiga, Brilinta | $110 | $169,228194 claims |
| Novo NordiskOzempic | $127 | $80,17558 claims |
| MerckVerquvo | $374 | $77,22186 claims |
| Johnson & JohnsonXarelto | $67 | $76,19083 claims |
| Esperion Therapeutics, Inc.Nexlizet | $226 | $44,97858 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Perry
- David KandzariAtlanta$3.7M
- Pradeep YadavAtlanta$3.5M
- Vasilis BabaliarosAtlanta$2.7M
- Megan CoylewrightCalhoun$2.3M
- William NicholsonAtlanta$2M
- Chandanreddy DevireddyAtlanta$1.9M
- Adam GreenbaumAtlanta$1.8M
- Amar PatelMarietta$1.8M
- Vivek RajagopalAtlanta$1.3M
- Christopher MeduriAtlanta$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.